Bio Rad Laboratories Inc
NYSE:BIO
Intrinsic Value
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. [ Read More ]
The intrinsic value of one
BIO
stock under the Base Case scenario is
422.72
USD.
Compared to the current market price of 285.28 USD,
Bio Rad Laboratories Inc
is
Undervalued by 33%.
Bio Rad Laboratories Inc's market capitalization is 8.1B USD.
BIO stock price is 285.28 USD.
BIO stock price (285.28 USD) is 33% less than its Intrinsic Value (422.72 USD).
BIO stock price (285.28 USD) is 37% less than its Relative Value (454.71 USD). Open Relative Valuation
BIO has upside potential of 47% compared to the average analyst price target.
Open Wall St Estimates
BIO's Revenue has been growing by 2% per year for the last 3 years.
BIO's ROIC (Return on Invested Capital) has decreased in the last 3 years from 4% to 3%.
BIO has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
BIO's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
BIO's Revenue has dropped by 5% over the past 12 months.
BIO has positive Operating Income for the last twelve months.
BIO's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
BIO has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
BIO has negative Net Debt. This means that the company has more cash and short-term investments (2B USD) than debt (1B USD).
BIO's ROE (Return on Equity) for the past 12 months is negative and is equal to -7%.
BIO has negative Net Income for the last twelve months.
BIO's ROE (Return on Equity) has significantly decreased in the last 3 years from 49% to -7%.
BIO's Altman Z-Score is very high and is equal to 3.01.
BIO has positive Free Cash Flow for the last twelve months.
BIO has positive Gross Profit for the last twelve months.
BIO's long-term assets (12B USD) exceed its long-term liabilties (4B USD).
BIO's D/E (Debt to Equity) is very low and is equal to 0.14.
BIO's short-term assets (3B USD) exceed its short-term liabilties (523m USD).
BIO doesn't generate enough operating income (366m USD) to safely cover interest payments on its debt (-47m USD).
Valuation Backtest
Bio Rad Laboratories Inc
Run backtest to discover the historical profit from buying and selling
BIO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bio Rad Laboratories Inc
Balance Sheet Decomposition
Bio Rad Laboratories Inc
| Current Assets | 3B |
| Cash & Short-Term Investments | 1.6B |
| Receivables | 489m |
| Other Current Assets | 952.2m |
| Non-Current Assets | 9.3B |
| Long-Term Investments | 7.7B |
| PP&E | 723.7m |
| Intangibles | 734.1m |
| Other Non-Current Assets | 94.9m |
| Current Liabilities | 522.8m |
| Accounts Payable | 429.2m |
| Accrued Liabilities | 180.3m |
| Other Current Liabilities | -86.7m |
| Non-Current Liabilities | 3B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 1.8B |
Earnings Waterfall
Bio Rad Laboratories Inc
|
Revenue
|
2.7B
USD
|
|
Cost of Revenue
|
-1.2B
USD
|
|
Gross Profit
|
1.4B
USD
|
|
Operating Expenses
|
-1.1B
USD
|
|
Operating Income
|
365.7m
USD
|
|
Other Expenses
|
-1B
USD
|
|
Net Income
|
-637.3m
USD
|
Free Cash Flow Analysis
Bio Rad Laboratories Inc
What is Free Cash Flow?
BIO Profitability Score
Profitability Due Diligence
Bio Rad Laboratories Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Bio Rad Laboratories Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
BIO Solvency Score
Solvency Due Diligence
Bio Rad Laboratories Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Bio Rad Laboratories Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIO Price Targets Summary
Bio Rad Laboratories Inc
According to Wall Street analysts, the average 1-year price target for
BIO
is 418 USD
with a low forecast of 353.5 USD and a high forecast of 497.7 USD.
Ownership
BIO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BIO Price
Bio Rad Laboratories Inc
| Average Annual Return | 16.63% |
| Standard Deviation of Annual Returns | 41.51% |
| Max Drawdown | -67% |
| Market Capitalization | 8.1B USD |
| Shares Outstanding | 28 815 000 |
| Percentage of Shares Shorted | 3.17% |
BIO News
Last Important Events
Bio Rad Laboratories Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Bio Rad Laboratories Inc
Company Profile
Bio Rad Laboratories Inc
Country
Industry
Market Cap
Dividend Yield
Description
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,900 full-time employees. Its segments include Life Science and Clinical Diagnostics. Its Life Science segment markets and develops, manufactures and markets approximately 9,000 reagents, apparatus and laboratory instruments that serve a global customer base. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Its Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. The company supplies approximately 3,000 different products that cover over 300 clinical diagnostic tests to the in vitro diagnostics (IVD) test market.
Contact
IPO
Employees
Officers
The intrinsic value of one
BIO
stock under the Base Case scenario is
422.72
USD.
Compared to the current market price of 285.28 USD,
Bio Rad Laboratories Inc
is
Undervalued by 33%.
You don't have any saved screeners yet
